Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
SGLT2 inhibitors (SGLT2i) or gliflozins are nowadays commonly prescribed in renal patients for nephroprotection. Erythrocytosis or polycythemia is one of its side effects, which is not well known. There has been reports in some studies related to its usage in heart failure patients. However, there is not much literature on this topic in renal patients. We present a case series of six patients with renal disease, who developed erythrocytosis after treatment with dapagliflozin.
This is a retrospective single center observational study of six adult patients with various renal conditions who developed high hemoglobin levels after treatment with dapagliflozin 10 mg once daily. Erythrocytosis was defined as Hb above 16.5 g/dl in patients with normal renal function and up to CKD stage 3. In CKD stage 4 patients, high hemoglobin (clinically relevant) was diagnosed when Hb was above 13.0 g/dl. Exclusion criteria included: cystic kidney disease, history of smoking, high altitude residence, renal tumour, renal artery stenosis, IgA nephropathy, chronic obstructive lung disease, obstructive sleep apnoea syndrome, heart failure and history of erythropoiesis stimulating agents or androgen therapy; or blood transfusion.
The mean age of the patients was 34.0 + 15.9 years. All the patients were males. Three patients had normal renal functions. Their basic kidney disease consisted of primary glomerulonephritis in two patients' and diabetic kidney disease in one patient. The mean hemoglobin in these patients was 16.8 + 0.23 g/dl. The other three patients had chronic kidney disease, with a mean serum creatinine of 2.0 + 0.8 mg%. The basic kidney disease in this group of patients comprised of biopsy proven chronic glomerulonephritis in all the patients. The mean hemoglobin in these patients was 16.0 + 1.96 g/dl. Serum erythropoietin level was done in one patient and it was 6.5 U/L. JAK 2 mutation was absent in this patient. The mean duration of therapy with dapagliflozin when the erythrocytosis was detected was 5.7 + 2.8 months. Dapagliflozin therapy was stopped in all the patients. One patient needed phlebotomy, since his packed cell volume exceeded 55%. The hemoglobin returned to normal in four patients after a mean period of three months after stopping dapagliflozin. Gliflozins were not restarted in any of these patients.
SGLT2 inhibitors are commonly prescribed in renal patents as per current clinical practice guidelines. Erythrocytosis may occur after therapy with dapagliflozin. It is important to remember this as one of the causes of high hemoglobin in patients with renal diseases including chronic kidney disease. It is important to rule out other causes of erythrocytosis in renal patients by appropriate history and investigations. Stoppage of dapagliflozin in these patients results in reversal of the condition.
